OR WAIT null SECS
August 02, 2011
Are biosimilars the next big thing or just the next big bubble?
July 21, 2011
A bill introduced by Senators Scott Brown (R-MA), Ron Wyden (D-OR), and John McCain (R-AZ) on July 13, 2011, aims to encourage states to reduce Medicaid spending by offering financial incentives to substitute generic drugs for branded ones where possible.
July 02, 2011
Follow-on versions of complex biologics require extensive expertise in development and regulatory procedures.
June 16, 2011
Merck and Hanwha Chemical have formed an exclusive global agreement to develop and a commercialize a biosimilar of Enbrel, a drug to treat moderate to severe plaque psoriasis, psoriatic arthritis, and moderate to severe rheumatoid arthritis.
June 02, 2011
FDA weighs multiple views regarding the Biologics Price Competition and Innovation Act.
May 12, 2011
FDA is asking for input on the development of a user-fee program for biosimilar and interchangeable biological product applications.
May 02, 2011
Innovator and generic-drug companies need to adapt to compete in the biosimilars market.
April 28, 2011
The IMS institute has released its report on the use of medicines in the United States during 2010.
April 06, 2011
Increased competition, the rising role of emerging markets, and targeted opportunities in niche segments are factors influencing the generic-drug market and related supply base.
March 31, 2011
The global market for biosimilars is set to grow from $243 million in 2010 to $3.7 billion in 2015, according to research from Datamonitor, an independent industry analyst company.